View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 30, 2020

BioNTech and Pfizer dose participants in Covid-19 vaccine trial

BioNTech and Pfizer have dosed participants in the first cohort of a Phase I/II clinical trial of Covid-19 vaccine candidate BNT162 in Germany.

Dosing in the trial was commenced on 23 April and 12 participants have received the vaccine so far.

The companies also intend to trial BNT162 in the US following regulatory approval.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena